This document is a USPTO patent application (US20260083859A1) for a "Sustained transgene expression of modified ERT2 peptide-suicide protein fusion polypeptides." The application describes novel targeting constructs that include mutants of the estrogen receptor alpha ligand binding domain (ER-LBD) for inducible cell death systems, along with methods for their use. The filing date was July 31, 2025.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it represents new intellectual property in the field of biotechnology and gene therapy, potentially impacting future research and development strategies for companies in the pharmaceutical and biotechnology sectors. Compliance officers should note this as a development in the IP landscape relevant to their organization's R&D or competitive intelligence.